A CaCC (TMEM16A) potentiator compound (ETD002, undisclosed structure; acquired by Roche from Enterprise Therapeutics) has entered Phase 1 clinical evaluation as a novel approach that has potential to provide benefit to all patients with cystic fibrosis (mentioned in [975]). Up-regulating chloride transport via CaCC is proposed to mitigate the effect of loss of chloride transport via CFTR in CF. See Enterprise Therapeutics’ reports of CaCC potentiator ETX001 for more detailed background information [235, 236]. This evidence concerns the gene ANO1 and cystic fibrosis.